ABSI
Absci Corporation
NASDAQ · Healthcare · Biotechnology · US
$8.88
+0.91%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−12.1x
Market Cap
$1.52B
MomentumView details →
1D Return
+0.91%
YTD Return
+149.45%
RSI (14)
47.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−12.1x
Market Cap
$1.52B
RSI (14)
47.4
MomentumView details →
1D Return
+0.91%
YTD Return
+149.45%
SummaryUpdated Jun 1, 2026
Absci Corporation (NASDAQ:ABSI) is a biotechnology company founded in 2011 and headquartered in Vancouver, Washington. The company went public in July 2021 and operates as a drug and target discovery company that leverages artificial intelligence to create biologic drug candidates. Absci has developed an integrated drug creation platform that unifies traditional drug discovery and cell line development processes, enabling the design of antibodies for previously challenging or "undruggable" targets.
Similar companies
Latest newsMore news →
Absci Corporation reported financial and operating results for the second quarter of 2026.24d agoAbsci completed a $100 million underwritten offering, including a $40 million strategic investment from Eli Lilly and Company.24d agoEli Lilly invested $40 million in Absci for equity, leading a $50 million funding round.72d ago